PTCT
What one share of PTC Therapeutics holds
Pharmaceutical Preparations
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs.
PTC Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $11.09 |
|---|---|
| Profit | −$0.38 |
| Capex (buildings and equipment) | $0.10 |
| Free cash flow | −$0.44 |
| Cash and investments | $26.75 |
| Debt | $7.16 |
| Book value | −$1.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.43 | −$4.17 | $0.05 | −$3.09 | — | — |
| 2017 | $4.96 | −$2.02 | $0.08 | −$0.34 | — | — |
| 2018 | $5.68 | −$2.75 | $0.15 | −$0.75 | — | — |
| 2019 | $5.22 | −$4.27 | $0.23 | −$1.91 | — | — |
| 2020 | $5.77 | −$6.64 | $0.27 | −$3.21 | — | — |
| 2021 | $7.64 | −$7.43 | $0.40 | −$3.97 | — | $0.02 |
| 2022 | $9.74 | −$7.79 | $0.45 | −$5.42 | — | −$4.75 |
| 2023 | $12.53 | −$8.37 | $0.38 | −$2.50 | — | −$10.81 |
| 2024 | $10.50 | −$4.73 | $0.08 | −$1.49 | — | −$14.13 |
| 2025 | $19.60 | $7.78 | $0.10 | $7.95 | — | −$2.52 |